Regulatory News: Cerenis Therapeutics (Paris:CEREN) (FR0012616852- CEREN) , an international biopharmaceutical company dedicated to the discovery and development of innovative HDL therapies (“good cholesterol”) for treating cardiovascular and metabolic diseases, today announces its full-year 2015….